Muhanned Abu-Hijleh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Muhanned Abu-Hijleh has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Kim Styrvoky
Affiliation Section of Interventional Pulmonology, Division of Thoracic Oncology, Department of Surgical Oncology, Orlando Health Cancer Institute, Orlando, Florida, United States of America
3 shared publications - Ashutosh Sachdeva
University of Maryland , Baltimore, MD
1 shared publication - Audra J. Schwalk
Division of Pulmonary and Critical Care Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
1 shared publication Brandon Jakubowski
Department of Medicine, Division of Pulmonary and Critical Care Medicine University of Texas Southwestern Medical Center, Dallas, TX
1 shared publication- Charlie Strange
Medical University of South Carolina
1 shared publication - Christian Ghattas
The Ohio State University , Wexner Medical Center, Columbus, OH
1 shared publication
Latest Publications
- Open Access
- 21 September 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
Metered-Dose Liquid Nitrogen Cryospray for Chronic Bronchitis: Results From the Prospective, Sham-Controlled Trial (SPRAY-CB)
Rationale: COPD with chronic bronchitis is characterized by productive cough with sputum and mucociliary dysfunction, contributing to morbidity and impaired quality of life. The RejuvenAir® System, a cryosurgical device delivering metered doses of medical-grade liquid nitrogen (i.e., Metered Cryospray [MCS]) to bronchial airways, may stimulate healthy epithelial cell regeneration. Objectives: To assess the safety and effectiveness of MCS treatment in patients with COPD and CB. Methods: Eligible patients were randomized 2:1 to receive two bronchoscopies with therapeutic mucus clearance, with or without MCS treatment (i.e., MCS or control group, respectively), 30–60 days apart. Safety and clinical effectiveness outcomes were assessed 12 months post-MCS treatment. Measurements and Main Results: Overall, 203 patients (MCS: N = 136; sham: N = 67) were evaluated. MCS-treated patients had significantly greater improvement in Total St. George’s Respiratory Questionnaire (SGRQ) scores versus controls (treatment difference [95% confidence interval; CI]: –5.9 [–11.6, –0.2]; p = 0.0422), and Total COPD Assessment Test (CAT) scores (treatment difference [95% CI]: –3.4 [–5.8, –1.0]; p = 0.005). Acute exacerbation of COPD (AECOPD; all severities) rates were 70.6% (MCS group) versus 67.2% (control group). Severe AECOPD rates were 21.3% (MCS group) versus 26.9% (control group). Periprocedural pneumothoraces rate per number of MCS treatments delivered was 3.6% (n/N=10/276). Eight deaths, 6 (4.3%; MCS) and 2 (2.9%; control), occurred during the study, none were device- or procedure-related. No unanticipated adverse device effects occurred. Conclusions: MCS treatment demonstrated significant improvement in Total SGRQ and CAT scores, greater reductions in severe AECOPD rates compared to sham, and an acceptable risk-benefit safety profile in patients with COPD and CB.
- 21 September 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
Open AccessMetered-Dose Liquid Nitrogen Cryospray for Chronic Bronchitis: Results From the Prospective, Sham-Controlled Trial (SPRAY-CB)
Rationale: COPD with chronic bronchitis is characterized by productive cough with sputum and mucociliary dysfunction, contributing to morbidity and impaired quality of life. The RejuvenAir® System, a cryosurgical device delivering metered doses of medical-grade liquid nitrogen (i.e., Metered Cryospray [MCS]) to bronchial airways, may stimulate healthy epithelial cell regeneration. Objectives: To assess the safety and effectiveness of MCS treatment in patients with COPD and CB. Methods: Eligible patients were randomized 2:1 to receive two bronchoscopies with therapeutic mucus clearance, with or without MCS treatment (i.e., MCS or control group, respectively), 30–60 days apart. Safety and clinical effectiveness outcomes were assessed 12 months post-MCS treatment. Measurements and Main Results: Overall, 203 patients (MCS: N = 136; sham: N = 67) were evaluated. MCS-treated patients had significantly greater improvement in Total St. George’s Respiratory Questionnaire (SGRQ) scores versus controls (treatment difference [95% confidence interval; CI]: –5.9 [–11.6, –0.2]; p = 0.0422), and Total COPD Assessment Test (CAT) scores (treatment difference [95% CI]: –3.4 [–5.8, –1.0]; p = 0.005). Acute exacerbation of COPD (AECOPD; all severities) rates were 70.6% (MCS group) versus 67.2% (control group). Severe AECOPD rates were 21.3% (MCS group) versus 26.9% (control group). Periprocedural pneumothoraces rate per number of MCS treatments delivered was 3.6% (n/N=10/276). Eight deaths, 6 (4.3%; MCS) and 2 (2.9%; control), occurred during the study, none were device- or procedure-related. No unanticipated adverse device effects occurred. Conclusions: MCS treatment demonstrated significant improvement in Total SGRQ and CAT scores, greater reductions in severe AECOPD rates compared to sham, and an acceptable risk-benefit safety profile in patients with COPD and CB.
- 21 December 2021
- Published by Wolters Kluwer Health in Journal of Bronchology & Interventional Pulmonology
- Vol. 29 (1) , e10-e11
Response to: Flexible Bedside Bronchoscopy Using Closed Sheath System and COVID-19 Patients
- 21 December 2021
- Published by Wolters Kluwer Health in Journal of Bronchology & Interventional Pulmonology
- Vol. 29 (1) , e10-e11
Response to: Flexible Bedside Bronchoscopy Using Closed Sheath System and COVID-19 Patients
- 28 August 2019
- Published by Springer Nature in Lung
- Vol. 197 (5) , 627-633
Intrabronchial Valves for Air Leaks After Lobectomy, Segmentectomy, and Lung Volume Reduction Surgery
Air leaks are common after lobectomy, segmentectomy, and lung volume reduction surgery (LVRS). This can increase post-operative morbidity, cost, and hospital length of stay. The management of post-pulmonary resection air leaks remains challenging. Minimally invasive effective interventions are necessary. The Spiration Valve System (SVS, Olympus/Spiration Inc., Redmond, WA, US) is approved by the FDA under humanitarian use exemption for management of prolonged air leaks.
- 28 August 2019
- Published by Springer Nature in Lung
- Vol. 197 (5) , 627-633
Intrabronchial Valves for Air Leaks After Lobectomy, Segmentectomy, and Lung Volume Reduction Surgery
Air leaks are common after lobectomy, segmentectomy, and lung volume reduction surgery (LVRS). This can increase post-operative morbidity, cost, and hospital length of stay. The management of post-pulmonary resection air leaks remains challenging. Minimally invasive effective interventions are necessary. The Spiration Valve System (SVS, Olympus/Spiration Inc., Redmond, WA, US) is approved by the FDA under humanitarian use exemption for management of prolonged air leaks.
- 4 December 2012
- Published by Springer Nature in Lung
- Vol. 191 (1) , 109-115
Linear Probe Endobronchial Ultrasound Bronchoscopy with Guided Transbronchial Needle Aspiration (EBUS–TBNA) in the Evaluation of Mediastinal and Hilar Pathology: Introducing the Procedure to a Teaching Institution
Background Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS–TBNA) is an important tool in the diagnosis of mediastinal and hilar pathology. We describe our experience with EBUS–TBNA performed in a teaching institution primarily under conscious sedation. Methods Patients who underwent EBUS–TBNA were included in this retrospective review. We focused on the diagnostic yield of EBUS–TBNA in relationship to the nature of the mediastinal or hilar lesions (suspected malignancy vs. benign disease), incremental 25 procedures aliquots, lymph node (LN) station, LN size, and the number of needle aspirations per LN station. Results Of the 212 patients who underwent EBUS–TBNA, 200 patients had adequate follow-up information and were included in this analysis. The procedure was performed under conscious sedation in 97 % of patients and 133 patients (67 %) were suspected to have malignancy before the procedure. A total of 690 TBNAs were performed from 294 LN stations. The mean number of LN stations sampled per procedure was 1.47 ± 0.6. The mean number of TBNAs per LN station was 2.35 ± 0.91. The mean number of TBNAs per procedure was 3.45 ± 1.2. The overall sensitivity, specificity, negative predictive value (NPV), and diagnostic accuracy for all procedures were 87.41 % (CI 80.76–91.99), 100 % (CI 93.12–100), 75.36 % (CI 64.04–84.01), and 90.91 % (CI 85.92–94.25), respectively. The NPV increased significantly after the initial 25 procedures and remained high thereafter. EBUS–TBNA was more accurate (96.12 % (CI 91.25–98.33)) with higher NPV (90.74 % (CI 80.09–95.98)) in patients with suspected malignancy compared with patients with suspected benign disease (79.31 % (CI 67.23–87.75), 20 % (7.05–45.19)). Samples from relatively smaller LN (>5 to ≤20 mm) and from all analyzed LN stations were similarly accurate with high sensitivity and NPV. Conclusions EBUS–TBNA allows safe real-time sampling of mediastinal and hilar lesions under conscious sedation with high diagnostic accuracy. The NPV is high and increased significantly after the initial 25–50 procedures. This is comparable to available surgical techniques, including mediastinoscopy, when malignancy is suspected. The NPV for specific benign disease remains low in our experience. The diagnostic yield is not affected by the LN station, size, or the number of passes per LN station.
- 4 December 2012
- Published by Springer Nature in Lung
- Vol. 191 (1) , 109-115
Linear Probe Endobronchial Ultrasound Bronchoscopy with Guided Transbronchial Needle Aspiration (EBUS–TBNA) in the Evaluation of Mediastinal and Hilar Pathology: Introducing the Procedure to a Teaching Institution
Background Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS–TBNA) is an important tool in the diagnosis of mediastinal and hilar pathology. We describe our experience with EBUS–TBNA performed in a teaching institution primarily under conscious sedation. Methods Patients who underwent EBUS–TBNA were included in this retrospective review. We focused on the diagnostic yield of EBUS–TBNA in relationship to the nature of the mediastinal or hilar lesions (suspected malignancy vs. benign disease), incremental 25 procedures aliquots, lymph node (LN) station, LN size, and the number of needle aspirations per LN station. Results Of the 212 patients who underwent EBUS–TBNA, 200 patients had adequate follow-up information and were included in this analysis. The procedure was performed under conscious sedation in 97 % of patients and 133 patients (67 %) were suspected to have malignancy before the procedure. A total of 690 TBNAs were performed from 294 LN stations. The mean number of LN stations sampled per procedure was 1.47 ± 0.6. The mean number of TBNAs per LN station was 2.35 ± 0.91. The mean number of TBNAs per procedure was 3.45 ± 1.2. The overall sensitivity, specificity, negative predictive value (NPV), and diagnostic accuracy for all procedures were 87.41 % (CI 80.76–91.99), 100 % (CI 93.12–100), 75.36 % (CI 64.04–84.01), and 90.91 % (CI 85.92–94.25), respectively. The NPV increased significantly after the initial 25 procedures and remained high thereafter. EBUS–TBNA was more accurate (96.12 % (CI 91.25–98.33)) with higher NPV (90.74 % (CI 80.09–95.98)) in patients with suspected malignancy compared with patients with suspected benign disease (79.31 % (CI 67.23–87.75), 20 % (7.05–45.19)). Samples from relatively smaller LN (>5 to ≤20 mm) and from all analyzed LN stations were similarly accurate with high sensitivity and NPV. Conclusions EBUS–TBNA allows safe real-time sampling of mediastinal and hilar lesions under conscious sedation with high diagnostic accuracy. The NPV is high and increased significantly after the initial 25–50 procedures. This is comparable to available surgical techniques, including mediastinoscopy, when malignancy is suspected. The NPV for specific benign disease remains low in our experience. The diagnostic yield is not affected by the LN station, size, or the number of passes per LN station.